A Phase 3 interventional study of E/C/F/TAF and E/C/F/TDF in HIV and HIV Infections, sponsored by Gilead Sciences. Completed at 117 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing elvitegravir in HIV Infections — none open to participants now, none under way, none of them phase 3. elvitegravir · HIV Infections.
Among the 11 studies testing elvitegravir in HIV Infections, this one is the 2nd largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 4th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →None of the 11 studies testing elvitegravir in HIV Infections is open now. The open studies under HIV Infections, anywhere →
elvitegravir: first FDA approval 2012 (STRIBILD), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9
First in 2007; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 872 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 252 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 4th largest by enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2012, is one of 26 in phase 3, and was the 66th registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing elvitegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
Drug: E/C/F/TAF · Drug: E/C/F/TDF Placebo
E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
Drug: E/C/F/TDF · Drug: E/C/F/TAF Placebo
After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
Drug: E/C/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablet administered orally once daily
Also known as: Genvoya®
150/150/200/300 mg FDC tablet administered orally once daily
Also known as: Stribild®
Tablet administered orally once daily
Tablet administered orally once daily
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Weeks 96 and 144
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Weeks 48, 96. and 144
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Change From Baseline in CD4+ Cell Count at Week 96
Time frame: Baseline; Week 96
Change From Baseline in CD4+ Cell Count at Week 144
Time frame: Baseline; Week 144
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.
Time frame: Baseline; Week 48
Percent Change From Baseline in Hip BMD at Week 96
Hip BMD was assessed by DXA scan.
Time frame: Baseline; Week 96
Percent Change From Baseline in Hip BMD at Week 144
Hip BMD was assessed by DXA scan.
Time frame: Baseline; Week 144
Percent Change From Baseline in Spine BMD at Week 48
Spine BMD was assessed by DXA scan.
Time frame: Baseline; Week 48
Percent Change From Baseline in Spine BMD at Week 96
Spine BMD was assessed by DXA scan.
Time frame: Baseline; Week 96
Percent Change From Baseline in Spine BMD at Week 144
Spine BMD was assessed by DXA scan.
Time frame: Baseline; Week 144
Change From Baseline in Serum Creatinine at Week 48
Time frame: Baseline; Week 48
Change From Baseline in Serum Creatinine at Week 96
Time frame: Baseline; Week 96
Change From Baseline in Serum Creatinine at Week 144
Time frame: Baseline; Week 144
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
Time frame: Up to 48 weeks
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
Time frame: Up to 96 weeks
Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
Time frame: Up to 144 weeks
Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 48
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 96
Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 144
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 48
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 96
Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
Time frame: Baseline; Week 144
Participants were enrolled at study sites in North America, Europe, and Asia. The first participant was screened on 26 December 2012. The last study visit occurred on 06 September 2017.
| Milestone | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Started | 438 | 434 |
| Completed | 368 | 356 |
| Not completed | 70 | 78 |
| Withdrew: Randomized but not treated | 3 | 2 |
| Withdrew: Adverse event | 4 | 14 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Pregnancy | 2 | 1 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Investigator's discretion | 5 | 2 |
| Withdrew: Non-compliance with study drug | 4 | 3 |
| Withdrew: Protocol violation | 4 | 3 |
| Withdrew: Withdrew consent | 23 | 24 |
| Withdrew: Lost to follow-up | 23 | 26 |
| Milestone | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Started | 90 | 95 |
| Completed | 90 | 94 |
| Not completed | 0 | 1 |
| Withdrew: Enrolled but not treated | 0 | 1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | 93.1 | 92.8 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Week 96 | 89.2 | 88.2 |
| Week 144 | 86.9 | 83.1 |
The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Week 48 | 86.4 | 87.3 |
| Week 96 | 84.4 | 83.6 |
| Week 144 | 84.6 | 80.1 |
| cells/µL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 235 ± 183.1 | 221 ± 178.9 |
| cells/µL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 96 | 285 ± 203.0 | 271 ± 208.1 |
| cells/µL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 144 | 323 ± 213.1 | 310 ± 207.2 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 | -0.865 ± 3.2532 | -3.200 ± 3.1759 |
Hip BMD was assessed by DXA scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 96 | -0.951 ± 3.8633 | -3.515 ± 3.9451 |
Hip BMD was assessed by DXA scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Hip BMD at Week 144 | -0.826 ± 4.6786 | -3.475 ± 4.1551 |
Spine BMD was assessed by DXA scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 48 | -1.337 ± 3.0715 | -2.956 ± 3.3524 |
Spine BMD was assessed by DXA scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 96 | -0.907 ± 4.0039 | -3.053 ± 3.9539 |
Spine BMD was assessed by DXA scan.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Spine BMD at Week 144 | -0.809 ± 4.5041 | -3.023 ± 4.3122 |
| mg/dL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 48 | 0.08 ± 0.110 | 0.11 ± 0.116 |
| mg/dL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 96 | 0.05 ± 0.109 | 0.07 ± 0.132 |
| mg/dL | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Change From Baseline in Serum Creatinine at Week 144 | 0.04 ± 0.115 | 0.08 ± 0.133 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Grade 1 | 25.8 | 32.3 |
| Grade 2 | 4.6 | 4.9 |
| Grade 3 | 0 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Grade 1 | 28.8 | 33.9 |
| Grade 2 | 5.1 | 5.8 |
| Grade 3 | 0.2 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant.
| percentage of participants | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Grade 1 | 31.3 | 37.1 |
| Grade 2 | 6.0 | 7.0 |
| Grade 3 | 0.2 | 0.2 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 | 6.9 (-23.3 to 42.1) | 51.2 (3.3 to 127.1) |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96 | 11.3 (-20.3 to 61.5) | 75.0 (9.9 to 182.6) |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144 | 37.4 (-6.0 to 87.3) | 106.9 (38.0 to 254.9) |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48 | -32.8 (-58.7 to 1.3) | 18.0 (-28.8 to 171.6) |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96 | -33.5 (-60.0 to 2.0) | 32.5 (-27.8 to 205.6) |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury.
| percent change | E/C/F/TAF | E/C/F/TDF |
|---|---|---|
| Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144 | -24.6 (-57.5 to 13.3) | 60.4 (-10.4 to 318.8) |
Collected over Double-Blind Phase: Up to a maximum of 194.1 weeks plus 30 days; Open-Label Phase: Up to a maximum of 48.3 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind: E/C/F/TAF | — | 73/435 (16.8%) | 380/435 (87.4%) |
| Double-Blind: E/C/F/TDF | — | 65/432 (15%) | 375/432 (86.8%) |
| Open-Label: E/C/F/TAF to E/C/F/TAF | — | 0/90 (0%) | 16/90 (17.8%) |
| Open-Label: E/C/F/TDF to E/C/F/TAF | — | 1/94 (1.1%) | 14/94 (14.9%) |
| Event | Double-Blind: E/C/F/TAF | Double-Blind: E/C/F/TDF | Open-Label: E/C/F/TAF to E/C/F/TAF | Open-Label: E/C/F/TDF to E/C/F/TAF |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 8/435 | 3/432 | 0/90 | 0/94 |
| InfluenzaInfections and infestations | 0/435 | 3/432 | 0/90 | 1/94 |
| Suicidal ideationPsychiatric disorders | 4/435 | 2/432 | 0/90 | 0/94 |
| CellulitisInfections and infestations | 0/435 | 3/432 | 0/90 | 0/94 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/435 | 3/432 | 0/90 | 0/94 |
| Meningitis viralInfections and infestations | 3/435 | 0/432 | 0/90 | 0/94 |
| Rectal haemorrhageGastrointestinal disorders | 0/435 | 2/432 | 0/90 | 0/94 |
| Suicide attemptPsychiatric disorders | 1/435 | 2/432 | 0/90 | 0/94 |
| Acute myocardial infarctionCardiac disorders | 2/435 | 1/432 | 0/90 | 0/94 |
| Abdominal painGastrointestinal disorders | 2/435 | 0/432 | 0/90 | 0/94 |
| Event | Double-Blind: E/C/F/TAF | Double-Blind: E/C/F/TDF | Open-Label: E/C/F/TAF to E/C/F/TAF | Open-Label: E/C/F/TDF to E/C/F/TAF |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 112/435 | 105/432 | 1/90 | 1/94 |
| Upper respiratory tract infectionInfections and infestations | 92/435 | 95/432 | 3/90 | 2/94 |
| NauseaGastrointestinal disorders | 73/435 | 84/432 | 2/90 | 0/94 |
| Viral upper respiratory tract infectionInfections and infestations | 69/435 | 64/432 | 2/90 | 1/94 |
| HeadacheNervous system disorders | 69/435 | 63/432 | 0/90 | 0/94 |
| Back painMusculoskeletal and connective tissue disorders | 50/435 | 61/432 | 0/90 | 0/94 |
| CoughRespiratory, thoracic and mediastinal disorders | 58/435 | 56/432 | 4/90 | 1/94 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 41/435 | 57/432 | 0/90 | 0/94 |
| SyphilisInfections and infestations | 55/435 | 56/432 | 4/90 | 2/94 |
| FatigueGeneral disorders | 49/435 | 47/432 | 0/90 | 0/94 |
Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| Mean | 35 ± 10.0 | 36 ± 10.5 | 35 ± 10.3 |
| Sex: Female, Male(Participants) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| Female | 71 | 56 | 127 |
| Male | 364 | 376 | 740 |
| Ethnicity (NIH/OMB)(Participants) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| Hispanic or Latino | 60 | 70 | 130 |
| Not Hispanic or Latino | 375 | 362 | 737 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 5 | 9 |
| Asian | 76 | 77 | 153 |
| Black | 94 | 81 | 175 |
| Native Hawaiian or Pacific Islander | 1 | 3 | 4 |
| White | 250 | 255 | 505 |
| Other | 10 | 11 | 21 |
| Region of Enrollment(Participants) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| United States | 252 | 250 | 502 |
| Japan | 4 | 6 | 10 |
| United Kingdom | 1 | 5 | 6 |
| Thailand | 63 | 58 | 121 |
| Switzerland | 6 | 12 | 18 |
| Spain | 42 | 42 | 84 |
| Canada | 23 | 23 | 46 |
| Austria | 15 | 8 | 23 |
| Belgium | 7 | 7 | 14 |
| Italy | 3 | 6 | 9 |
| Australia | 19 | 15 | 34 |
| HIV-1 RNA (log10 copies/mL)(log10 copies/mL) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| Mean | 4.55 ± 0.682 | 4.55 ± 0.674 | 4.55 ± 0.678 |
| HIV-1 RNA Category(Participants) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| ≤ 100,000 copies/mL | 331 | 336 | 667 |
| > 100,000 to ≤ 400,000 copies/mL | 79 | 72 | 151 |
| > 400,000 copies/mL | 25 | 24 | 49 |
| CD4 Cell Count(cells/µL) | E/C/F/TAF | E/C/F/TDF | Total |
|---|---|---|---|
| Mean | 437 ± 223.7 | 426 ± 212.3 | 432 ± 218.0 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 117 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2012 to primary completion in Aug 2014, 20 months.
Results were first posted in Jan 2016, 1 year 4 months after primary completion. A results delay was requested in Jun 2014.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide